Moderna MRNA shares have surged 143% in the past month, driven largely by recently announced positive late-stage results for a personalized mRNA-based cancer therapy being developed in partnership with Merck MRK.
Oncology Win Highlights Moderna’s Potential Beyond Vaccines
The latest results give investors a stronger reason to view the company’s mRNA platform as having potential beyond vaccines targeting infectious disease. The personalized mRNA-based therapy, called intismeran autogene (V940/mRNA-4157), delivered positive results in high-risk melanoma patients whose tumors had been removed through surgery. When combined with Merck’s blockbuster oncology drug Keytruda, the therapy met the study’s primary endpoint of recurrence-free survival, or the length of time patients remain free of cancer recurrence. The combination also achieved a key secondary endpoint of distant metastasis-free survival, indicating that patients remained free of cancer spread for longer.
The significance of these results extends beyond melanoma. Moderna and Merck are studying intismeran in several other cancer types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma. Positive results across these programs could substantially expand the therapy’s commercial opportunity and give Moderna an important growth avenue outside its vaccine portfolio.
While the recent development represents a potentially significant new growth driver for Moderna and strengthens the long-term value of its mRNA platform, investors need to weigh the company’s broader fundamentals before determining how to play the stock.
Moderna Continues Expanding Respiratory Portfolio
Moderna continues to expand its respiratory portfolio as it works to build growth opportunities beyond its COVID-19 vaccine business. The company has broadened its presence into RSV with mResvia and seasonal influenza with mFlusiva. In the meantime, Moderna’s pipeline includes additional respiratory programs, such as a combination influenza and COVID-19 vaccine, as well as candidates targeting diseases including bird flu and norovirus.
The company also remains committed to the COVID-19 market. MRNA recently secured FDA approval for updated 2026/2027 formulations of Spikevax and mNexspike, demonstrating that it is continuing to compete in the COVID-19 segment even as demand has normalized. Maintaining a presence in the market while expanding into other respiratory categories could help Moderna diversify its vaccine business and reduce its reliance on COVID-19 sales over the longer term.
Moderna Has a Clear Roadmap for Future Growth
The success of intismeran is particularly significant in light of Moderna’s three-horizon strategy outlined at an investor event earlier this year. The company places intismeran in Horizon 1 alongside its established infectious-disease vaccines and rare-disease therapeutics. These programs represent the company’s near-term opportunities as Moderna works to build multiple growth engines beyond its COVID-19 franchise.
Moderna’s longer-term ambitions become more evident in the later horizons. Horizon 2 includes additional mRNA-based therapeutic approaches already moving through development, including cancer antigen therapies, T-cell engagers, cell-therapy enhancers and an investigational therapy for multiple sclerosis. Horizon 3 comprises earlier-stage technologies, including in-vivo CAR-T and CAR-M cell therapies, which could become future growth platforms for the company.
Taken together, the three horizons show that Moderna is looking to evolve from a vaccine-maker into a diversified pharmaceutical company. The success with intismeran therefore represents not only an important milestone for one oncology program but also a meaningful proof point for Moderna’s strategy to apply its technology across multiple therapeutic areas.
Competition Poses a Concern
Moderna faces established competitors across the respiratory markets it is targeting. In RSV, mResvia competes with Pfizer’s PFE Abrysvo and GSK’s Arexvy.
The company recently entered the seasonal influenza market, which is dominated by large players such as Sanofi, CSL Seqirus and GSK. The competitive landscape could become even more challenging as GSK advances its own mRNA-based flu vaccine into late-stage development, following positive phase II results.
The competitive pressure also extends to COVID-19 vaccines, where Moderna faces Pfizer/BioNTech BNTX and Sanofi/Novavax. Competition could intensify further in combination vaccines as these companies develop candidates that target both influenza and COVID-19, potentially increasing the pressure on pricing and market share.
In oncology, the challenge is broader than competing for market share in a single indication. BioNTech is also developing an individualized mRNA-based cancer immunotherapy in collaboration with Roche, putting the two companies on a path to compete in the emerging personalized oncology market. As Moderna seeks to expand intismeran across multiple tumor types, its ability to differentiate the therapy, secure regulatory approvals and execute a successful commercial launch will be critical to realizing its potential.
MRNA Stock Performance, Valuation & Estimates
Year to date, MRNA stock has skyrocketed nearly 400% compared with the industry’s 10% growth, as seen in the chart below. During this timeframe, the stock also outdid the broader Medical sector and the S&P 500 Index.
MRNA Stock Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
From a valuation standpoint, Moderna appears to be trading at a premium compared to the industry. Based on the price/sales (P/S) ratio, the company’s shares currently trade at 26 times trailing 12-month sales, higher than 2.58 for the industry.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Moderna’s 2026 loss per share have improved from $8.57 to $8.50 in the past 30 days. However, the consensus mark for 2027 has narrowed from $4.67 to $4.52 during the same period.
Image Source: Zacks Investment Research
How to Play MRNA Stock?
Moderna’s outlook is improving as the company develops growth opportunities across oncology while expanding into other therapeutic areas. However, the turnaround is likely to take time. Products such as mFlusiva are still in the early stages of building commercial momentum, while the larger potential from oncology remains dependent on additional clinical, regulatory and commercial milestones.
Although estimates for Moderna’s losses have improved, a meaningful recovery in financial performance is likely to develop gradually as newer products gain traction and pipeline opportunities move closer to commercialization. Investors should therefore focus less on a rapid recovery in financial performance and more on whether Moderna can steadily establish new sources of growth.
Therefore, we advise investors with a long-term horizon to stay invested in this Zacks Rank #3 (Hold). The improving earnings outlook and expanding pipeline strengthen Moderna’s long-term growth prospects, but investors should remain patient as the company works to translate its pipeline investments into sustainable commercial growth.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).